Spotlight
AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition
The acquisition allows AbbVie to establish its presence in the ovarian cancer market with Immunogen’s Elahere.
Latest news
FDA accepts Merck's Keytruda plus Padcev sBLA to treat urothelial cancer
The company has submitted the sBLA based on data from the Phase III KEYNOTE-A39 trial.
Generation bio cuts 40% of staff in blow for non-viral gene therapy sector
The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.
Cybin reports positive results from major depressive disorder trial
In the trial, tested doses of CYB003 demonstrated to have a favourable safety and tolerability profile.
AML cell therapy trials to watch in 2024 targeting GvHD
Following the approval of NiCord earlier this year, there are more candidates coming to late-stage trials looking to target GvHD.
Pharma's engagement with healthcare providers has slipped in recent years
Changing trends show a reduction in HCP contact with the pharma industry and an increased prioritisation of in-person contact.
CTO Europe 2023: Fostering diverse oncology trials remains a challenge
Experts at the clinical conference continued to explore ways to improve representation in clinical trials and the regulatory push behind it.
BioVie reports protocol deviations in Phase III Alzheimer's trial
Despite violations at 15 out of 39 sites involved in the study, BioVie reported positive data from its trial investigating NE3107.
In our previous edition
Pharma Decoded
FDA opens investigation into secondary cancer risk with CAR-T therapies
30 Nov 2023
Pharma Decoded
Pharma's path to Net Zero: Targeting Scope 3 emissions
29 Nov 2023
Pharma Decoded
Sanofi and Regeneron's Dupixent scores second win in Phase III COPD trial
28 Nov 2023
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward